It also points to the need for better strategies to make these treatments more accessible and available to those who need them. Prior to this research, a small study of 106 postmenopausal women published in 2024 in the medical journal Menopause found that those who were on both MHT and the GLP-1 drug semaglutide had lost about 16 percent of their total body weight after a year, compared to 12 percent for women on a GLP-1 alone
The new approval reinforces Krazatis potential across tumor types, the company said in a press release
Now you might wonder, "What makes each GLP-1 different, and which is right for me?" That must be a discussion between you and your doctor, as a 2021 review 7 tells us the most notable differences between GLP-1 receptor agonistslike pharmacokinetics 8 (how the body interacts with the medication), dosing frequency, and administrationcan impact the GLP-1 RA's efficacy, tolerability, and patient satisfaction
That kind of weight loss can lead to other health improvements like lowered blood pressure, blood sugar, and some blood fats, and can improve joint pain and sleep apnea
